<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03635866</url>
  </required_header>
  <id_info>
    <org_study_id>18-00601</org_study_id>
    <nct_id>NCT03635866</nct_id>
  </id_info>
  <brief_title>PET/MRI Study of Men With Highly Suspicious MRI Lesions That Showed no Clinically Significant Prostate Cancer Following MRI Fusion Targeted Biopsy</brief_title>
  <official_title>PET/MRI Study of Men With Highly Suspicious MRI Lesions That Showed no Clinically Significant Prostate Cancer Following MRI Fusion Targeted Biopsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The principal aim of this study is to determine if PET/MRI imaging with 18-F fluciclovine&#xD;
      (Axumin) identifies those men with false negative MRI fusion targeted biopsy (MRFTB) of&#xD;
      PI-RADS 4 and 5 lesions. PI-RADS 4 and 5 MRI lesions are highly suspicious for clinically&#xD;
      significant prostate cancer and require future repeat MRI imaging and possible repeat&#xD;
      prostate biopsy depending on the results of the repeat MRI. Men, who had negative MRFTB&#xD;
      within past 12 months of PI- RADS 4 or 5 MRI lesion will be included in this diagnostic&#xD;
      study. The repeat MRI is standard of care at NYU Langone Health. The investigation aspect of&#xD;
      the study is to perform an Axumin scan the same day as the MRI. Those men with persistent&#xD;
      highly suspicious lesions will under MRFTB. The biopsy results will be compared with&#xD;
      intensity of Axumin uptake within the prostate. The urologist will have the discretion to&#xD;
      biopsy Axumin avid lesions not detected by MRI.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2, 2019</start_date>
  <completion_date type="Actual">October 9, 2020</completion_date>
  <primary_completion_date type="Actual">October 9, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with negative prostate biopsy</measure>
    <time_frame>12 Months</time_frame>
    <description>This will be measured by determining is if PET imaging with 18-F fluciclovine (Axumin) identifies those men with prior negative MRFTBs of PI-RADS 4 and 5 lesions who harbor clinically significant prostate cancer</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>prior negative MRFTB of PI-RADS 4 and 5 lesions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diagnosed withing 12 months of initial diagnostic cancer biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Fluciclovine PET/MRI</intervention_name>
    <description>It is unknown how many negative MRFTBs of PI-RADS 4 lesions are false negative biopsies or false positive tests.</description>
    <arm_group_label>prior negative MRFTB of PI-RADS 4 and 5 lesions</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The participant has undergone MRFTB of an MRI lesion at the Department of Urology or&#xD;
             at NYU Langone Health within past 12 months and has signed informed consent to&#xD;
             participate in the NYU Urology prostate biopsy database.&#xD;
&#xD;
          -  The most recent MRFTB of a PIRADS 4 or 5 lesion did not show clinically significant&#xD;
             prostate cancer.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The urologist who performed the initial MRFTB does not feel a repeat MRI is indicated.&#xD;
&#xD;
          -  Any contraindication to prostate biopsy including untreated urinary tract infection&#xD;
&#xD;
          -  Prior allergic reaction to axumin&#xD;
&#xD;
          -  Patient refuses MRI&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herbert Lepor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York University Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>August 15, 2018</study_first_submitted>
  <study_first_submitted_qc>August 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2018</study_first_posted>
  <last_update_submitted>December 3, 2020</last_update_submitted>
  <last_update_submitted_qc>December 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The objective of the study is: to determine if PET imaging with 18-F fluciclovine identifies those men with prior negative MRFTBs of PI-RADS 4&amp;5</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

